Surfactant effect on the physicochemical characteristics of cationic solid lipid nanoparticles

Botto, Chiara; Mauro, Nicolò; Amore, Erika; Martorana, Elisabetta; Giammona, Gaetano; Bondı̀, Maria Luisa

doi:10.1016/j.ijpharm.2016.11.052

Cited by 37 publications

(26 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effect of different sets of SLNs containing different concentrations of DDAB was tested in colorectal carcinoma (HCT-116) and bronchial epithelial (16-HBE) human cell lines [7], showing that at the highest tested SLN concentration (500 µg/mL,~40 µg/mL of DDAB), the loss of cell viability was 20% for both cell lines. These concentrations are significantly lower than those tested in our work (Figure 1), showing that toxicity might also be dependent on the other components of the formulation (Precirol ATO 5 and the surfactants Brij 76 [7]) and/or of the cell line. The IC 50 values reported by Botto et al [7], together with the observed low toxicity, is in line with our results.…”

Section: Cell Linementioning

confidence: 99%

“…In this regard, the components of nanoparticles aiming to deliver pharmaceutically active substances by routes, such as intravenous, oral, nasal pulmonary, must be of high grade and biocompatible to physiological systems. Other features to consider are the physicochemical properties of nanoparticles that influence stability and shelf-life of formulations, which can be improved by selecting the appropriate lipids and surfactants in the right combinations [2,[5][6][7]. Surfactants are used to disperse the solid-lipid matrix in water thereby reducing the surface tension and energy to control the shape and prevent the risk of nanoparticles' aggregation under shelf life [6,8,9].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Soft Cationic Nanoparticles for Drug Delivery: Production and Cytotoxicity of Solid Lipid Nanoparticles (SLNs)

et al. 2019

View full text Add to dashboard Cite

The surface properties of nanoparticles have decisive influence on their interaction with biological barriers (i.e., living cells), being the concentration and type of surfactant factors to have into account. As a result of different molecular structure, charge, and degree of lipophilicity, different surfactants may interact differently with the cell membrane exhibiting different degrees of cytotoxicity. In this work, the cytotoxicity of two cationic solid lipid nanoparticles (SLNs), differing in the cationic lipids used as surfactants CTAB (cetyltrimethylammonium bromide) or DDAB (dimethyldioctadecylammonium bromide), referred as CTAB-SLNs and DDAB-SLNs, respectively, was assessed against five different human cell lines (Caco-2, HepG2, MCF-7, SV-80, and Y-79). Results showed that the cationic lipids used in SLN production highly influenced the cytotoxic profile of the particles, with CTAB-SLNs being highly cytotoxic even at low concentrations (IC50 < 10 µg/mL, expressed as CTAB amount). DDAB-SLNs produced much lower cytotoxicity, even at longer exposure time (IC50 from 284.06 ± 17.01 µg/mL (SV-80) to 869.88 ± 62.45 µg/mL (MCF-7), at 48 h). To the best of our knowledge, this is the first report that compares the cytotoxic profile of CTAB-SLNs and DDAB-SLNs based on the concentration and time of exposure, using different cell lines. In conclusion, the choice of the right surfactant for biological applications influences the biocompatibility of the nanoparticles. Regardless the type of drug delivery system, not only the cytotoxicity of the drug-loaded nanoparticles should be assessed, but also the blank (non-loaded) nanoparticles as their surface properties play a decisive role both in vitro and in vivo.

show abstract

Section: Cell Linementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Soft Cationic Nanoparticles for Drug Delivery: Production and Cytotoxicity of Solid Lipid Nanoparticles (SLNs)

et al. 2019

View full text Add to dashboard Cite

show abstract

“…[103,104] Like the above liposomes, SLNs are typically colloidal particles with an average diameter between 10 and 1000 nm. [103,104] Like the above liposomes, SLNs are typically colloidal particles with an average diameter between 10 and 1000 nm.…”

Section: Solid Lipid Nanoparticlesmentioning

confidence: 99%

Rational Design of Nanocarriers for Intracellular Protein Delivery

et al. 2019

View full text Add to dashboard Cite

Protein/antibody therapeutics have exhibited the advantages of high specificity and activity even at an extremely low concentration compared to small molecule drugs. However, they are accompanied by unfavorable physicochemical properties such as fragile tertiary structure, large molecular size, and poor penetration of the membrane, and thus the clinical use of protein drugs is hindered by inefficient delivery of proteins into the host cells. To overcome the challenges associated with protein therapeutics and enhance their biopharmaceutical applications, various protein‐loaded nanocarriers with desired functions, such as lipid nanocapsules, polymeric nanoparticles, inorganic nanoparticles, and peptides, are developed. In this review, the different strategies for intracellular delivery of proteins are comprehensively summarized. Their designed routes, mechanisms of action, and potential therapeutics in live cells or in vivo are discussed in detail. Furthermore, the perspective on the new generation of delivery systems toward the emerging area of protein‐based therapeutics is presented as well.

show abstract

“…While being among the most effective carriers for both hydrophilic and hydrophobic drugs, such as liposomes, the solid, lipophilic nucleus of SLNs may have difficulty carrying RNA molecules that are hydrophilic and polyanionic. Therefore, it can be used successfully for gene delivery by addition of cationic lipids to SLNs which provide a positive surface potential [34].…”

Section: Solid Lipid Nanoparticlesmentioning

confidence: 99%

Applications of Lipidic and Polymeric Nanoparticles for siRNA Delivery

Şenel¹,

Büyükköroğlu²

2019

Antisense Therapy

View full text Add to dashboard Cite

The antisense technology that emerged with the discovery of RNA interference nearly 20 years ago has gained a significant place in gene therapy. siRNA, one of two important components of RNA interference, efficiently downregulates gene expression in human cells, so it has the potential to eradicate disease. siRNA delivery systems, which can be applied both systemically and locally in different diseases, have gained significant importance. Naked small RNAs can be delivered directly to cells, but because of their instability, exposure to enzyme degradation, and difficulties in reaching/entering the target cell or tissue in blood stream, these initiatives are failing. For this reason, the method of delivery or encapsulation of siRNA is usually required. Various nanoparticles, nanocapsules, emulsions, micelle systems, metal ion nanoparticles, and nanoconjugates have been used for siRNA delivery. In these transport systems, lipidic and polymeric systems are very attractive due to their advantages such as being biodegradable and biocompatible, safety, being able to electrostatically bind to RNA, long-term stability, well-illuminated structure and features, simple and easy production, etc. Issues such as particle size, zeta potential, and stability of siRNA-loaded system should be taken into consideration in the development of siRNA delivery systems.

show abstract

Surfactant effect on the physicochemical characteristics of cationic solid lipid nanoparticles

Cited by 37 publications

References 18 publications

Soft Cationic Nanoparticles for Drug Delivery: Production and Cytotoxicity of Solid Lipid Nanoparticles (SLNs)

Soft Cationic Nanoparticles for Drug Delivery: Production and Cytotoxicity of Solid Lipid Nanoparticles (SLNs)

Rational Design of Nanocarriers for Intracellular Protein Delivery

Applications of Lipidic and Polymeric Nanoparticles for siRNA Delivery

Contact Info

Product

Resources

About